Castration-resistant prostate cancer - Hormone therapy redux

Journal of Clinical Oncology

Volumn 28, Issue 9, 2010, Pages 1447-1449

  Tolcher, Anthony W ^a   Cooper, Josh ^a  

^a START Center for Cancer Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ANTIANDROGEN; DOCETAXEL; KETOCONAZOLE; MITOXANTRONE; ANDROGEN; ANTINEOPLASTIC AGENT;

ANDROGEN DEPRIVATION THERAPY; BLOOD TOXICITY; CANCER HORMONE THERAPY; CANCER RESISTANCE; CASTRATION; EDITORIAL; HUMAN; HYPERTENSION; HYPOKALEMIA; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; UNSPECIFIED SIDE EFFECT; MALE; METABOLISM; NOTE; ORCHIECTOMY; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 77951916303     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.3781     Document Type: Editorial

References (12)

1. Petrylak DP, Tangen CM, Hussain MHA, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004 (Pubitemid 39315318)
2. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004 (Pubitemid 39315317)
3. Schroder FH: Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma. Prog Clin Biol Res 359:93-103, 1990
4. Loose DS, Kan PB, Hirst MA, et al: Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest 71:1495-1499, 1983 (Pubitemid 13098940)
5. Bok RA, Small EJ: The treatment of advanced prostate cancer with ketoconazole: Safety issues. Drug Saf 20:451-458, 1999 (Pubitemid 29231659)
6. Harris KA, Weinberg V, Bok RA, et al: Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urology 168:542-545, 2002 (Pubitemid 34793290)
7. Small EJ, Halabi S, Dawson NA, et al: Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J Clin Oncol 22:1025-1033, 2004 (Pubitemid 41095034)
8. O'Donnell A, Judson I, Dowsett M, et al: Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90:2317-2325, 2004
9. Ryan CJ, Smith MR, Fong L, et al: Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28:1481-1488, 2010
10. Attard G, Reid AHM, Yap TA, et al: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563-4571, 2008
11. Attard G, Reid AHM, A'Hern R, et al: Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3742-3748, 2009
12. Reid AHM, Attard G, Danila DC, et al: Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28:1489-1495, 2010